Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30825799 | 1.00 | PLA2G2A (0.38) | PLA2G2APLA2G10PLA2G1BPLA2G5MGLL | |
| SCHEMBL29193319 | 1.00 | PLA2G2A (0.38) | PLA2G2APLA2G10PLA2G1BPLA2G5MGLL | |
| SCHEMBL25244010 | 1.00 | PLA2G2A (0.38) | PLA2G2APLA2G10PLA2G1BPLA2G5MGLL | |
| SCHEMBL29193316 | 1.00 | PLA2G2A (0.38) | PLA2G2APLA2G10PLA2G1BPLA2G5MGLL | |
| SCHEMBL29193344 | 0.86 | MGLL (0.35) | MGLLEPAS1PTGS1PTGS2PGR | |
| SCHEMBL29193343 | 0.86 | MGLL (0.35) | MGLLEPAS1PTGS1PTGS2PGR | |
| SCHEMBL30825803 | 0.86 | MGLL (0.35) | MGLLEPAS1PTGS1PTGS2PGR | |
| SCHEMBL25287207 | 0.84 | PLA2G2A (0.37) | PLA2G2APLA2G10PLA2G1BPLA2G5CTSG | |
| SCHEMBL25287173 | 0.84 | PLA2G2A (0.37) | PLA2G2APLA2G10PLA2G1BPLA2G5CTSG | |
| SCHEMBL25293058 | 0.84 | PLA2G2A (0.37) | PLA2G2APLA2G10PLA2G1BPLA2G5CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034182-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12116380-B2 | Phospholipid compounds and methods of making and using the same | GILEAD SCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116380-B2 | Phospholipid compounds and methods of making and using the same | PHOSPHO1, SGMS1, SGMS2 | PLA2G2A 26/4885PLA2G10 39/4885PLA2G1B 24/4885 |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PHOSPHO1, SGMS1, SGMS2 | PLA2G2A 26/4885PLA2G10 39/4885PLA2G1B 24/4885 |
| US-20250034182-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PHOSPHO1, SGMS1, SGMS2 | PLA2G2A 26/4885PLA2G10 39/4885PLA2G1B 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.